[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100397712":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":25,"centralContacts":29,"locations":39,"responsibleParty":57,"collaborators":10,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":10,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":10,"studyType":72,"phases":10,"briefSummary":73,"conditions":74,"keywords":76,"overallStatus":41,"whyStopped":10,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Wayne State University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"African Americans with RRMS",null,"Participants who are diagnosed with relapsing multiple sclerosis and who have chosen to start or recently started using ocrelizumab as their disease modifying therapy. Age range: 18 to 60 years old. Ethnicity: Self-described as African American.",[13],"Other: Observation of Ocrelizumab as Treatment in RRMS Patients",{"label":15,"type":10,"description":16,"interventionNames":17},"Caucasian American with RRMS","Participants who are diagnosed with relapsing multiple sclerosis and who have chosen to start or recently started using ocrelizumab as their disease modifying therapy. Age range: 18 to 60 years old. Ethnicity: Self-described as Caucasian American.",[13],[19],{"type":6,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"Observation of Ocrelizumab as Treatment in RRMS Patients","It is decided by the patient and their physician to begin taking ocrelizumab PRIOR to study enrollment. The study is only observing the effects of ocrelizumab as a pre-decided treatment option for a patient's MS.",[9,15],[24],"Observing Ocrelizumab Use",[26],{"name":27,"affiliation":5,"role":28},"Evanthia Bernitsas, MD","PRINCIPAL_INVESTIGATOR",[30,35],{"name":31,"role":32,"phone":33,"phoneExt":10,"email":34},"Zahid Latif","CONTACT","3139660473","zahidlatif@wayne.edu",{"name":36,"role":32,"phone":37,"phoneExt":10,"email":38},"Kelly Jia","313-966-9407","xjia@med.wayne.edu",[40],{"facility":5,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"RECRUITING","Detroit","Michigan","48201","United States","US",{"type":48,"coordinates":49},"Point",[50,51],-83.04575,42.33143,{"lat":51,"lon":50},[54,56],{"name":31,"role":32,"phone":55,"phoneExt":10,"email":34},"313-966-0473",{"name":36,"role":32,"phone":37,"phoneExt":10,"email":38},{"type":28,"investigatorFullName":27,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Prinipal Investigator","100397712","investigating-the-effect-of-ocrelizumab-in-african-americans-and-caucasians-with-relapsing-multiple-sclerosis-100397712",false,"NCT04458688","Investigating the Effect of Ocrelizumab in African Americans and Caucasians With Relapsing Multiple Sclerosis","Investigating the Effect of Ocrelizumab in African Americans and Caucasians With Relapsing Multiple Sclerosis: a Novel, Advanced Multimodal MRI and Optical Coherence Tomography-Angiography (OCTA) Study","Inclusion Criteria:\n\n1. Patients who have chosen to start ocrelizumab and for whom ocrelizumab is determined to be the most appropriate standard-of-care disease modifying therapy (DMT) by the treating neurologist.\n2. May be treatment naive, or had suboptimal response to no more than one DMT after an adequate course of treatment (defined as treatment duration of 6+ months).\n3. Age 18 to 60 years old.\n4. Ethnicity: self-identified as African American or Caucasian.\n5. Clinically definite relapsing remitting multiple sclerosis (RRMS) per 2017 revised McDonald criteria.\n6. EDSS from 0 to 6 (inclusive) at baseline visit.\n7. Able to give informed consent.\n8. Able to have MRI scans.\n\nExclusion Criteria:\n\n1. Treatment with another monoclonal antibody, including but not limited to natalizumab, alemtuzumab, daclizumab.\n2. Failed 2 or more DMTs.\n3. Treatment with immunosuppressant agents, such as chemotherapeutic agents.\n4. Claustrophobia.\n5. Allergy to contrast.\n6. Significant medical problems that the PI determines will interfere with the conduct of the study.\n7. Relapse or use of corticosteroids within 30 days prior to baseline visit.\n8. Pregnancy.\n9. History of kidney or liver insufficiency.\n10. History of malignancy.","ALL","18 Years","60 Years",{"count":70,"type":71},80,"ESTIMATED","OBSERVATIONAL","The investigators intend to examine the effects of ocrelizumab use in African American multiple sclerosis disease course compared to Caucasian disease course utilizing imaging measures with magnetic resonance imaging (MRI) and optical coherence tomography angiography (OCT-A)..",[75],"Multiple Sclerosis, Relapsing-Remitting",[77,78,79,80],"multiple sclerosis","ocrelizumab","magnetic resonance imaging (MRI)","optical coherence tomography angiography (OCTA)","2022-06-03",{"date":83,"type":84},"2022-06-06","ACTUAL",{"date":86,"type":84},"2021-11-20",{"date":88,"type":71},"2030-12",{"name":5,"class":6},1]